

Immunotherapeutics Committee

Immunotherapeutics Committee

Leadership

Co-Chairs:	Siwen Hu-Lieskovan, MD, PhD
	Katerina Politi, PhD
Executive Officer:	Anne Chiang, MD, PhD
Statisticians:	Michael LeBlanc, PhD
	Katie Minichiello, MS
	Matt Chansky, BS
Designates	
Data Coordinators:	Michele Counts
Pharmaceutical Science:	Jordan P. McPherson, PharmD
	Kimberly McConnell, PharmD
Sr. Protocol Project Manager:	Chris Kippola, BS

Time/Location

Friday, September 19, 2025 9:00 a.m. - 11:00 a.m. Room: Water Tower (Concourse Level, West Tower)

Agenda

	Agenua
9:00 - 9:05 am	Welcome & Introductions Siwen Hu-Lieskovan & Katerina Politi SWOG Immunotherapeutics Committee Co-Chairs
9:05 – 9:20 am	iMATCH Pilot Update: Stage II Update Paul Swiecicki, Katerina Politi, Siwen Hu-Lieskovan S2101 Study Chairs
9:20 – 9:25 am	Q&A
9:25 – 9:45 am	Personalized Cancer Vaccines for Kidney Cancer David Braun, MD, PhD Assistant Professor of Medicine (Medical Oncology) Louis Goodman and Alfred Gilman Yale Scholar
9:45 – 9:55 am	Q&A
9:55 – 10:10 am	ECOG-ACRIN Immunotherapeutics Update Yana G. Najjar, MD Associate Profession of Medicine, Univ of Pittsburgh Director, Clinical and Translational Research Center
10:10 – 10:20 am	Q&A

10:20 – 10:35 am Alliance Immunotherapeutics Update

David Kozono, MD, PhD

Assistant Professor of Radiation Oncology, Harvard

Medical School

Director, Thoracic Radiation Oncology

10:35 – 10:45 am Q & A

10:45 – 10:55 am Final Comments & Closing Remarks

Siwen Hu-Lieskovan & Katerina Politi

SWOG Immunotherapeutics Committee Co-Chairs

Active Study

S2101, "Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study." Drs. Hu-Lieskovan, Swiecicki and Politi. Activation: 10/14/22.

Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Spring 2025 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

None this cycle

Immunotherapeutics Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	<i>52101</i>
Essentia Health NCI Community Oncology Research Program	1
Froedtert and the Medical College of Wisconsin LAPS	4
Heartland Cancer Research NCORP	1
Michigan Cancer Research Consortium NCORP	1
New Mexico Minority Underserved NCORP	1
Northwestern University LAPS	1
Pacific Cancer Research Consortium NCORP	1
Regents of the University of Michigan	13
University of Arkansas for Medical Sciences	2
University of Utah - Huntsman Cancer Institute LAPS	10
ALLIANCE	8
ECOG-ACRIN	7
NRG	5
Total	55

